The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Phase I study of FT538, an iPSC-derived NK cell therapy, with daratumumab in R/R multiple myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, outlines the rationale of a Phase I study evaluating FT538, an off-the-shelf induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy in combination with daratumumab in relapsed/refractory (R/R) multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.
